McGowan Group Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-158,507
Closed -$18.9M 133
2024
Q3
$18.9M Sell
158,507
-69,970
-31% -$9.33M 2.49% 12
2024
Q2
$32.6M Buy
228,477
+1,289
+0.6% +$171K 4.54% 6
2024
Q1
$29.2M Sell
227,188
-1,136
-0.5% -$135K 4.21% 8
2023
Q4
$23.6M Sell
228,324
-2,474
-1% -$245K 3.79% 8
2023
Q3
$21M Buy
+230,798
New +$20.3M 3.31% 8

Other funds holding NVO

McGowan Group Asset Management's NVO Position: Q4 2024 in Review

McGowan Group Asset Management sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 158,507 shares — an estimated $18.9M sold.

McGowan Group Asset Management first reported a position in NVO in Q3 2023 and held it in 5 quarters. The position peaked at $32.6M in Q2 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • McGowan Group Asset Management reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • McGowan Group Asset Management sold 158,507 Novo Nordisk shares in Q4 2024, an estimated $18.9M.
  • McGowan Group Asset Management first reported a position in Novo Nordisk in Q3 2023 and held it in 5 quarters.
  • McGowan Group Asset Management's Novo Nordisk position peaked at $32.6M in Q2 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on McGowan Group Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.